Key result
PKCbetaII inhibition with betaIIV5-3 reverses HF in rat models by restoring cardiac protein quality control.
Why the study?
Does selective PKCbetaII inhibition with betaIIV5-3 re-establish cardiac protein quality control and reverse heart failure in preclinical models?
Population
Failing human hearts from two different etiologies and rat models of myocardial infarction-induced and…
Comparison
Sustained and selective PKCbetaII inhibition… vs Control hearts and selective inhibition of…
Design
Preclinical
Authors
Loading...
May support PKCbetaII inhibition as a target in heart failure; hypothesis-generating in rat models and requires clinical translation.
Does selective PKCbetaII inhibition with betaIIV5-3 re-establish cardiac protein quality control and reverse heart failure in preclinical models?
Selective inhibition of PKCbetaII reverses heart failure in preclinical models by restoring cardiac protein quality control, suggesting a novel therapeutic target.
Ferreira et al. (2012) studied Heart failure. PKCbetaII inhibition with betaIIV5-3 vs. Control hearts / untreated models was evaluated on Cardiac protein quality control and heart failure reversal. Sustained and selective PKCbetaII inhibition with betaIIV5-3 re-established cardiac protein quality control and reversed heart failure in rat models of myocardial infarction and hypertension.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: